Enodia Therapeutics

#Enodia Therapeutics #Pfizer #Protein degradation #Sec61 inhibitors #Small molecules

Enodia Therapeutics and Pfizer to develop Sec61-targeting small molecules 

Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, has entered into a research collaboration and license agreement with Pfizer to discover and develop Sec61 inhibitors.   The collaboration aims to accelerate the discovery and advancement of novel small-molecule… Read More

#News

Protein degradation
#Enodia Therapeutics #Institut Pasteur #Protein degradation

Start-up takes a new approach to targeted protein degradation

Argobio and the Institut Pasteur have launched Enodia Therapeutics, a French biotech company dedicated to block and degrade disease-causing proteins for treating cancer, inflammatory diseases and viral infections.  Enodia’s first-in-class treatments target the translocon, a key gateway for protein secretion in the cell.  “With the convergence of an unprecedented diverse… Read More

#Business & Investment #News